# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN
- Date: 2026-10-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Seven-month review. **S**

## History of present illness

Ms. Mankiller returns seven months after her diagnosis. She has had no drooping eyelids, double vision or trouble chewing since the summer; only after a very long day does she feel her arms tire. Prednisone is now 15 mg each morning, and she stopped trimethoprim-sulfamethoxazole when the dose fell below 20 mg last week, as planned. She takes azathioprine 150 mg daily; the blood tests at the Cherokee Nation clinic two and six weeks after the dose increase were normal and the nurse called her each time. She has returned to full-time work. She sleeps better on the lower prednisone dose. Home blood pressure readings average 116/74. She drinks about 2.5 liters of water a day and has had no flank pain or blood in the urine. She would like fewer pyridostigmine tablets. **S**

| Element | Detail |
|---|---|
| Strength | MG-ADL 1: minimal manifestation status |
| Medicines | Prednisone 15 mg; azathioprine 150 mg; pyridostigmine 60 mg four times daily; trimethoprim-sulfamethoxazole stopped |
| Work | Full time |
| Kidneys | Home blood pressure about 116/74; no symptoms |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No ptosis or double vision |
| Musculoskeletal | Positive | Arms tire only after very long days |
| Genitourinary | Negative | No flank pain or blood in the urine |
| Constitutional | Negative | No fever or infections; weight down 1 kg |
| Psychiatric | Negative | Mood good; sleeping better; PHQ-2 score 0 |

5 systems reviewed. **S**

## Current medications

- Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before meals **S**
- Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeks **S**
- Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily **S**
- Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food **S**
- Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 63.6 kg; BMI 23.9 kg/m². All vital signs are synthetic.

Hemoglobin: 12.9 g/dL; White cell count: 5.4 10*3/uL; Platelets: 238 10*3/uL; Creatinine: 0.8 mg/dL; eGFR (CKD-EPI 2021): 99 mL/min/1.73 m²; ALT: 23 U/L; Hemoglobin A1c: 5.6%; Urine albumin-to-creatinine ratio: 16 mg/g; Forced vital capacity (seated): 3.62 L; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.8 g/dL at baseline, 12.9 g/dL at this visit **S**
- White cell count: 6.9 10*3/uL at baseline, 5.4 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 238 10*3/uL at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 102 mL/min/1.73 m² at baseline, 99 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 23 U/L at this visit **S**
- Hemoglobin A1c: 5.3% at baseline, 5.6% at this visit **S**
- Urine albumin-to-creatinine ratio: 14 mg/g at baseline, 16 mg/g at this visit **S**
- Forced vital capacity (seated): 3.3 L at baseline, 3.62 L at this visit **S**

## Immunizations given today

- Inactivated influenza vaccine, this season **S**
- COVID-19 vaccine, mRNA, this season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/76 mm Hg; weight 63.6 kg |
| Eyes | No ptosis after one minute of upgaze; no diplopia |
| Neurological | Strength 5 of 5 without fatigue; speech normal |
| Abdomen | Both kidneys palpable, non-tender |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Generalized myasthenia gravis in minimal manifestation status** (G70.00). MG-ADL 1 at seven months, after thymectomy, on prednisone 15 mg and azathioprine 150 mg. Newer targeted therapies are not needed. **S**
   - Pyridostigmine 60 mg three times daily.
   - Continue the prednisone taper toward 7.5 mg or less over the next three months, then more slowly.
   - Continue azathioprine 150 mg daily.
2. **Azathioprine monitoring** (Z79.624). White cells 5.4, hemoglobin 12.9, platelets 238 and ALT 23: no toxicity. **S**
   - Blood count and liver tests every three months at the Cherokee Nation clinic.
3. **Glucocorticoid therapy** (Z79.52). Hemoglobin A1c 5.6 percent, at the upper limit of normal; weight steady. **S**
   - Hemoglobin A1c again in six months.
   - Eye examination at the Cherokee Nation eye clinic next month.
4. **Autosomal dominant polycystic kidney disease** (Q61.2). eGFR 99 and urine albumin 16 mg/g: normal. Home blood pressure averages 116/74 mm Hg, below 130/85, so no medicine is needed; KDIGO advises an individualized approach in this range. **S**
   - eGFR and urine albumin yearly; home blood pressure monthly.
   - Water 2 to 3 liters a day; less salt; no NSAIDs.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | MG-ADL score and post-intervention status | Every visit | Completed today | 1; minimal manifestation status |
| Imaging | Forced vital capacity | Every visit while on dose changes | Completed today | 3.62 L |
| Laboratory | Blood count on azathioprine | Every three months after the first two months | Completed today | Hemoglobin 12.9 g/dL; white cells 5.4; platelets 238 |
| Laboratory | Liver tests and creatinine on azathioprine | Every three months | Completed today | ALT 23 U/L; creatinine 0.80 mg/dL; eGFR 99 |
| Laboratory | Hemoglobin A1c on glucocorticoids | Periodically | Completed today | 5.6 percent |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly in ADPKD | Completed today | 16 mg/g |
| Examination | Blood pressure | Every visit | Completed today | 118/76 mm Hg in clinic; home average 116/74 |
| Imaging | Bone density (DXA) | Every one to three years on glucocorticoids by risk | Up to date | Normal five months ago; repeat if glucocorticoids continue beyond a year |
| Examination | Eye examination on glucocorticoids | Yearly | Ordered | Booked next month at the Cherokee Nation eye clinic |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with azathioprine | Not indicated | Stopped last week when prednisone fell below 20 mg |
| Medication safety | Medicines that can worsen myasthenia gravis | With every new prescription | Completed today | None prescribed; the list reviewed |
| Medication safety | Vaccines on immunosuppression | Seasonal | Completed today | Inactivated influenza and COVID-19 vaccines today |
| Survey | Depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 0 |
| Self-management | Water intake, salt, home blood pressure and laboratory access | Every visit | Completed today | About 2.5 liters a day; home readings monthly; standing orders at the Cherokee Nation clinic working |

## Goal progress

- A confirmed diagnosis and treatment plan within three weeks. Outcome by 2026-03-23: AChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeks. **S**
- Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less. Outcome by 2026-10-12: MG-ADL 7 at diagnosis, 1 at seven months; prednisone 15 mg and still tapering. **S**
- No myasthenic crisis, and she knows the warning signs and the medicines to avoid. Outcome by 2026-10-12: No crisis; FVC 3.25 to 3.62 L; she carries a wallet card and the list of medicines to avoid. **S**
- Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs. Outcome by 2026-10-12: eGFR normal; urine albumin normal; home blood pressure about 116/74 without medicine. **S**
- Return to full-time work for the Cherokee Nation. Outcome by 2026-10-12: Back at work full time from the seventh month. **S**

## Medication changes

- Stopped: Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals **S**
- Started: Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before meals **S**

## Guideline basis

- Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020), Myasthenia Gravis Foundation of America task force (Neurology)
- Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016), Myasthenia Gravis Foundation of America task force (Neurology)
- KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025), Kidney Disease: Improving Global Outcomes (KDIGO)
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022), American College of Rheumatology

## Follow-up

- Blood count and liver tests every three months at the Cherokee Nation clinic. Eye examination next month. Neuromuscular neurology in three months. Review here in three months. **S**

